Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mimedx Group Inc (MDXG)

Mimedx Group Inc (MDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,021,904
  • Shares Outstanding, K 148,102
  • Annual Sales, $ 348,880 K
  • Annual Income, $ 42,420 K
  • EBIT $ 54 M
  • EBITDA $ 60 M
  • 60-Month Beta 1.64
  • Price/Sales 3.01
  • Price/Cash Flow 21.37
  • Price/Book 4.39

Options Overview Details

View History
  • Implied Volatility 227.87% (+15.84%)
  • Historical Volatility 38.10%
  • IV Percentile 94%
  • IV Rank 39.98%
  • IV High 535.62% on 12/05/25
  • IV Low 22.85% on 09/04/25
  • Expected Move (DTE 19) 0.26 (3.70%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 154
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 1.45
  • Today's Open Interest 2,379
  • Open Int (30-Day) 5,068
  • Expected Range 6.65 to 7.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.09
  • Number of Estimates 1
  • High Estimate 0.09
  • Low Estimate 0.09
  • Prior Year 0.07
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.62 +4.23%
on 12/02/25
7.45 -7.32%
on 12/18/25
+0.02 (+0.29%)
since 11/26/25
3-Month
6.32 +9.09%
on 11/19/25
7.97 -13.43%
on 11/05/25
-0.04 (-0.58%)
since 09/26/25
52-Week
5.79 +19.17%
on 06/20/25
9.71 -28.94%
on 01/02/25
-2.49 (-26.52%)
since 12/26/24

Most Recent Stories

More News
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC...

MDXG : 6.90 (-2.54%)
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and...

MDXG : 6.90 (-2.54%)
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds...

MDXG : 6.90 (-2.54%)
MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following...

MDXG : 6.90 (-2.54%)
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release...

MDXG : 6.90 (-2.54%)
MiMedx: Q3 Earnings Snapshot

MiMedx: Q3 Earnings Snapshot

MDXG : 6.90 (-2.54%)
MIMEDX Announces Record Revenue for Third Quarter 2025

Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History  Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted...

MDXG : 6.90 (-2.54%)
MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29

MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the...

MDXG : 6.90 (-2.54%)
MiMedx Group (MDXG) Receives a Buy from Lake Street

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on MiMedx Group, with a price target of $12.00. The company’s shares closed yesterday at $7.31.Elevate Your Investing...

MDXG : 6.90 (-2.54%)
Craig-Hallum Reaffirms Their Buy Rating on MiMedx Group (MDXG)

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on MiMedx Group. The company’s shares closed yesterday at $7.31.Elevate Your Investing Strategy: Take advantage...

MDXG : 6.90 (-2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the...

See More

Key Turning Points

3rd Resistance Point 7.50
2nd Resistance Point 7.32
1st Resistance Point 7.11
Last Price 6.90
1st Support Level 6.71
2nd Support Level 6.53
3rd Support Level 6.32

See More

52-Week High 9.71
Fibonacci 61.8% 8.21
Fibonacci 50% 7.75
Fibonacci 38.2% 7.29
Last Price 6.90
52-Week Low 5.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar